Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma

Patricia A. Young, MD, Fabio D Mataveli, MDPhDMBA

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-137784

Published: 2020

Journal Articles

Granulocyte Colony-Stimulating Factor (G-CSF) Interactions with Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma

Daria Gaut, MD, Kevin Tang, BS, BA, Myung Sim, PhD, Tuyen Duong, Joshua Sasine, MD PhD, Patricia A. Young, MD

Blood (2019) 134 (Supplement_1): 4109.

https://doi.org/10.1182/blood-2019-122195

Published: 2019

Journal Articles

Consolidative High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients with Primary Central Nervous System (CNS) Lymphoma or Non-Hodgkin Lymphoma with CNS Involvement Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen

Patricia A. Young, MD, Daria Gaut, MD, Davis A. Kimaiyo, Jonathan A. Grotts, John P Chute, MD, Gary J. Schiller, MD, John M. Timmerman, MD, Sven de Vos, Herbert A. Eradat, MD MS

Blood (2018) 132 (Supplement 1): 4611.

https://doi.org/10.1182/blood-2018-99-117225

Published: 2018

Journal Articles

Analysis of Programmed Death Ligand 1 (PD-L1) Expression in Diffuse Large B Cell Lymphomas (DLBCL) in HIV-Negative Versus HIV-Positive Patients

Chun Chao, PhD, Patricia A Young, MD, Lanfang Xu, PhD, Michael J. Silverberg, PhD MPH, Jonathan W. Said, MD, John M. Timmerman, MD

Blood (2015) 126 (23): 1462.

https://doi.org/10.1182/blood.V126.23.1462.1462

Published: 2015

Journal Articles

Antibody-Interferon-Alpha Fusion Protein Therapy for the Treatment of B-Cell Non-Hodgkin Lymphoma: Enhanced ADCC, Inhibition of Proliferation, and In Vivo Eradication of CD20+ Human Lymphomas

John M. Timmerman, MD, Kristopher K Steward, PhD, Reiko E Yamada, Patricia A Young, MD, Dena M. Minning, MD PhD, Raj K Sachdev, PhD, Michael J Gresser, PhD, Sanjay D Khare, PhD, Sherie L Morrison, PhD

Blood (2015) 126 (23): 2762.

https://doi.org/10.1182/blood.V126.23.2762.2762

Published: 2015

NARROW

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma

Granulocyte Colony-Stimulating Factor (G-CSF) Interactions with Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma

Consolidative High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients with Primary Central Nervous System (CNS) Lymphoma or Non-Hodgkin Lymphoma with CNS Involvement Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen

Analysis of Programmed Death Ligand 1 (PD-L1) Expression in Diffuse Large B Cell Lymphomas (DLBCL) in HIV-Negative Versus HIV-Positive Patients

Antibody-Interferon-Alpha Fusion Protein Therapy for the Treatment of B-Cell Non-Hodgkin Lymphoma: Enhanced ADCC, Inhibition of Proliferation, and In Vivo Eradication of CD20+ Human Lymphomas

Email alerts

ASH Publications

American Society of Hematology

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma

Granulocyte Colony-Stimulating Factor (G-CSF) Interactions with Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma

Consolidative High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients with Primary Central Nervous System (CNS) Lymphoma or Non-Hodgkin Lymphoma with CNS Involvement Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen

Analysis of Programmed Death Ligand 1 (PD-L1) Expression in Diffuse Large B Cell Lymphomas (DLBCL) in HIV-Negative Versus HIV-Positive Patients

Antibody-Interferon-Alpha Fusion Protein Therapy for the Treatment of B-Cell Non-Hodgkin Lymphoma: Enhanced ADCC, Inhibition of Proliferation, and In Vivo Eradication of CD20+ Human Lymphomas

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only